Definium Therapeutics (DFTX) Non Operating Income (2019 - 2026)
Definium Therapeutics (DFTX) reported Non Operating Income of -$17.9 million for Q1 2026, down 302.91% year-over-year from $8.8 million in Q1 2025, and down 525.54% quarter-over-quarter from -$2.9 million in Q4 2025.
Definium Therapeutics (DFTX) Non Operating Income (2019 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has 7 years of Non Operating Income data on file, last reported at -$17.9 million in Q1 2026.
- Non Operating Income for Q1 2026 came in at -$17.9 million, down 302.91% year-over-year; the trailing twelve-month figure through Mar 2026 was -$44.2 million (down 221.88% YoY), and the FY2025 annual result was -$17.5 million, down 267.08% from the prior year.
- Non Operating Income fell to -$17.9 million in Q1 2026 per DFTX's latest filing, from -$2.9 million in the prior quarter.
- Over five years, Non Operating Income peaked at $18.6 million in Q2 2024 and troughed at -$32.2 million in Q1 2024.
- A 5-year average of -$1.9 million and a median of -$14000.0 in 2022 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income plunged 7420.37% in 2023, then surged 34351.85% in 2024.
- A 5-year view of Non Operating Income shows it stood at $9.0 million in 2022, then plunged by 118.44% to -$1.7 million in 2023, then sank by 37.37% to -$2.3 million in 2024, then fell by 25.41% to -$2.9 million in 2025, then tumbled by 525.54% to -$17.9 million in 2026.
- Business Quant data shows DFTX's Non Operating Income at -$17.9 million in Q1 2026, -$2.9 million in Q4 2025, and -$21.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Definium Therapeutics | 2.46 Bn | 2.09 Bn | - | -17.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.88 Mn |
| Dec 31, 2025 | -2.86 Mn |
| Sep 30, 2025 | -21.60 Mn |
| Jun 30, 2025 | -1.84 Mn |
| Mar 31, 2025 | 8.81 Mn |
| Dec 31, 2024 | -2.28 Mn |
| Sep 30, 2024 | 11.11 Mn |
| Jun 30, 2024 | 18.60 Mn |
| Mar 31, 2024 | -32.20 Mn |
| Dec 31, 2023 | -1.66 Mn |
| Sep 30, 2023 | 3.69 Mn |
| Jun 30, 2023 | 54,000.00 |
| Mar 31, 2023 | -3.95 Mn |
| Dec 31, 2022 | 9.00 Mn |
| Sep 30, 2022 | 498,000.00 |
| Jun 30, 2022 | -14,000.00 |
| Mar 31, 2022 | 54,000.00 |
| Dec 31, 2021 | -428,000.00 |
| Sep 30, 2021 | 31,000.00 |
| Jun 30, 2021 | -32,000.00 |